These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31344021)

  • 1. Progress in Testing for and Treatment of Hepatitis C Virus Infection Among Persons Who Inject Drugs - Georgia, 2018.
    Stvilia K; Spradling PR; Asatiani A; Gogia M; Kutateladze K; Butsashvili M; Zarkua J; Tsertsvadze T; Sharvadze L; Japaridze M; Kuchuloria T; Gvinjilia L; Tskhomelidze I; Gamkrelidze A; Khonelidze I; Sergeenko D; Shadaker S; Averhoff F; Nasrullah M
    MMWR Morb Mortal Wkly Rep; 2019 Jul; 68(29):637-641. PubMed ID: 31344021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Screening and Treatment in National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016.
    Nasrullah M; Sergeenko D; Gvinjilia L; Gamkrelidze A; Tsertsvadze T; Butsashvili M; Metreveli D; Sharvadze L; Alkhazashvili M; Shadaker S; Ward JW; Morgan J; Averhoff F
    MMWR Morb Mortal Wkly Rep; 2017 Jul; 66(29):773-776. PubMed ID: 28749925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia.
    Averhoff F; Shadaker S; Gamkrelidze A; Kuchuloria T; Gvinjilia L; Getia V; Sergeenko D; Butsashvili M; Tsertsvadze T; Sharvadze L; Zarkua J; Skaggs B; Nasrullah M
    J Hepatol; 2020 Apr; 72(4):680-687. PubMed ID: 31811882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the way to Hepatitis C elimination in the Republic of Georgia-Barriers and facilitators for people who inject drugs for engaging in the treatment program: A formative qualitative study.
    Chikovani I; Ompad DC; Uchaneishvili M; Sulaberidze L; Sikharulidze K; Hagan H; Van Devanter NL
    PLoS One; 2019; 14(4):e0216123. PubMed ID: 31034530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016.
    Gvinjilia L; Nasrullah M; Sergeenko D; Tsertsvadze T; Kamkamidze G; Butsashvili M; Gamkrelidze A; Imnadze P; Kvaratskhelia V; Chkhartishvili N; Sharvadze L; Drobeniuc J; Hagan L; Ward JW; Morgan J; Averhoff F
    MMWR Morb Mortal Wkly Rep; 2016 Oct; 65(41):1132-1135. PubMed ID: 27764081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C prevalence and risk factors in Georgia, 2015: setting a baseline for elimination.
    Hagan LM; Kasradze A; Salyer SJ; Gamkrelidze A; Alkhazashvili M; Chanturia G; Chitadze N; Sukhiashvili R; Shakhnazarova M; Russell S; Blanton C; Kuchukhidze G; Baliashvili D; Hariri S; Ko S; Imnadze P; Drobeniuc J; Morgan J; Averhoff F
    BMC Public Health; 2019 May; 19(Suppl 3):480. PubMed ID: 32326913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three Years of Progress Toward Achieving Hepatitis C Elimination in the Country of Georgia, April 2015-March 2018.
    Tsertsvadze T; Gamkrelidze A; Chkhartishvili N; Abutidze A; Sharvadze L; Kerashvili V; Butsashvili M; Metreveli D; Gvinjilia L; Shadaker S; Nasrullah M; Adamia E; Zeuzem S; Afdhal N; Arora S; Thornton K; Skaggs B; Kuchuloria T; Lagvilava M; Sergeenko D; Averhoff F
    Clin Infect Dis; 2020 Aug; 71(5):1263-1268. PubMed ID: 31563938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C treatment uptake among patients who have received methadone substitution treatment in the Republic of Georgia.
    Stvilia K; Vephkvadze N; Gamkrelidze A; Khonelidze I; Getia V; Tsereteli M; Gvinjilia L; Kuchuloria T
    Public Health; 2021 Jun; 195():42-50. PubMed ID: 34051674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons Learned From Global Hepatitis C Elimination Programs.
    Handanagic S; Shadaker S; Drobeniuc J; Tsereteli M; Alkhazashvili M; Adesigbin C; Adamu I; Adabe R; Agwuocha C; Adisa O; Azania A; Boeke CE; Ngwije A; Serumondo J; Armstrong PA
    J Infect Dis; 2024 May; 229(Supplement_3):S334-S341. PubMed ID: 37739781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Barriers to hepatitis C treatment among secondary needle and syringe program clients and opportunities to intervene.
    Gunn J; McNally S; Ryan J; Layton C; Bryant M; Walker S; O'Mahony C; Pedrana A
    Int J Drug Policy; 2021 Oct; 96():103387. PubMed ID: 34330571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Launch of a Nationwide Hepatitis C Elimination Program--Georgia, April 2015.
    Mitruka K; Tsertsvadze T; Butsashvili M; Gamkrelidze A; Sabelashvili P; Adamia E; Chokheli M; Drobeniuc J; Hagan L; Harris AM; Jiqia T; Kasradze A; Ko S; Qerashvili V; Sharvadze L; Tskhomelidze I; Kvaratskhelia V; Morgan J; Ward JW; Averhoff F
    MMWR Morb Mortal Wkly Rep; 2015 Jul; 64(28):753-7. PubMed ID: 26203628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study.
    Williams B; Howell J; Doyle J; Thompson AJ; Draper B; Layton C; Latham N; Bramwell F; Membrey D; Mcpherson M; Roney J; Stoové M; Hellard ME; Pedrana A
    Int J Drug Policy; 2019 Oct; 72():91-98. PubMed ID: 31129023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C among people who inject drugs in Tbilisi, Georgia: an urgent need for prevention and treatment.
    Bouscaillou J; Champagnat J; Luhmann N; Avril E; Inaridze I; Miollany V; Labartkava K; Kirtadze I; Butsashvili M; Kamkamidze G; Pataut D
    Int J Drug Policy; 2014 Sep; 25(5):871-8. PubMed ID: 24529802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High coverage needle/syringe programs for people who inject drugs in low and middle income countries: a systematic review.
    Des Jarlais DC; Feelemyer JP; Modi SN; Abdul-Quader A; Hagan H
    BMC Public Health; 2013 Jan; 13():53. PubMed ID: 23332005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Barriers of linkage to HCV viremia testing among people who inject drugs in Georgia.
    Butsashvili M; Abzianidze T; Kamkamidze G; Gulbiani L; Gvinjilia L; Kuchuloria T; Tskhomelidze I; Gogia M; Tsereteli M; Miollany V; Kikvidze T; Shadaker S; Nasrullah M; Averhoff F
    Subst Abuse Treat Prev Policy; 2022 Mar; 17(1):23. PubMed ID: 35346265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights from a national survey in 2021 and from modelling on progress towards hepatitis C virus elimination in the country of Georgia since 2015.
    Walker JG; Tskhomelidze I; Shadaker S; Tsereteli M; Handanagic S; Armstrong PA; Gamkrelidze A; Vickerman P
    Euro Surveill; 2023 Jul; 28(30):. PubMed ID: 37498534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Home-based hepatitis C self-testing in people who inject drugs and men who have sex with men in Georgia: a protocol for a randomised controlled trial.
    Shilton S; Stvilia K; Japaridze M; Tsereteli N; Usharidze D; Phevadze S; Jghenti M; Mozalevskis A; Markby J; Luhmann N; Johnson C; Nabeta P; Ongarello S; Reipold EI; Gamkrelidze A
    BMJ Open; 2022 Sep; 12(9):e056243. PubMed ID: 36691209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C screening in Lithuania: first-year results and scenarios for achieving WHO elimination targets.
    Petkevičienė J; Voeller A; Čiupkevičienė E; Razavi-Shearer D; Liakina V; Jančorienė L; Kazėnaitė E; Zaksas V; Urbonas G; Kupčinskas L
    BMC Public Health; 2024 Apr; 24(1):1055. PubMed ID: 38622549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.
    Akiyama MJ; Cleland CM; Lizcano JA; Cherutich P; Kurth AE
    Lancet Infect Dis; 2019 Nov; 19(11):1255-1263. PubMed ID: 31540840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study.
    Valerio H; Alavi M; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Holden J; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Dore GJ; Grebely J
    Clin Infect Dis; 2021 Jul; 73(1):e69-e78. PubMed ID: 32421194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.